Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.45 |
| ▸ | FYN | P06241 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4491543 | 0.82 | FYN (0.49) | FYNPIK3CAATRMAPTBRD4 | |
| SCHEMBL31747436 | 0.79 | MKNK1 (0.46) | FYNPIK3CAATR | |
| SCHEMBL16709634 | 0.79 | KEAP1 (0.49) | PIK3CAMAPTTSHRNPC1RAB9A | |
| SCHEMBL29938346 | 0.77 | SCN9A (0.43) | FYNMAPTTSHRNPC1RAB9A | |
| SCHEMBL30444814 | 0.75 | RIPK2 (0.46) | MAPK1PIK3CD | |
| SCHEMBL27656773 | 0.74 | FYN (0.47) | FYNPIK3CAATRMAPTBRD4 | |
| SCHEMBL16709594 | 0.74 | SCN4A (0.59) | MAPTMAPK1CASP1NPC1RAB9A | |
| SCHEMBL29938392 | 0.73 | ALDH1A1 (0.44) | MAPTNPC1RAB9A | |
| SCHEMBL18068142 | 0.73 | BCHE (0.36) | CFTRPDE4B | |
| SCHEMBL20575911 | 0.72 | CFTR (0.50) | CFTRSMPD3FYNPIK3CAATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203197-A1 | Phosphodiesterase 4 inhibitors | HOPPER ALLEN | 2007-08-30 | — | — | US | claimed |
| CN-1809559-A | Pyrazole derivatives as phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2006-07-26 | — | — | CN | claimed |
| EP-1631568-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2006-03-08 | — | — | EP | claimed |
| US-20040229918-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2004-11-18 | — | — | US | claimed |
| WO-2004094411-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-11-04 | — | — | WO | claimed |
| US-20090221661-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2009-09-03 | — | — | US | disclosed |
| US-7495017-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-20070203197-A1 | Phosphodiesterase 4 inhibitors | HOPPER ALLEN | 2007-08-30 | — | — | US | disclosed |
| US-7226930-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICAL CORPORATION (US) | 2007-06-05 | — | — | US | disclosed |
| CN-1809559-A | Pyrazole derivatives as phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2006-07-26 | — | — | CN | disclosed |
| EP-1631568-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20040229918-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2004-11-18 | — | — | US | disclosed |
| WO-2004094411-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203197-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | CFTR 825/4885SMPD3 57/4885FYN 2438/4885 |
| US-20090221661-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE12 | CFTR 825/4885SMPD3 57/4885FYN 2438/4885 |
| US-20040229918-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | CFTR 825/4885SMPD3 57/4885FYN 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.